Vectorised antibody takes ‘innovative approach’ to ALS treatment
VectorY Therapeutics has announced that the first participant has been dosed in its Phase I/II PIONEER-ALS clinical trial of VTx-002 in people with amyotrophic lateral sclerosis (ALS).
VTx-002 is a first-in-class vectorised antibody designed to holistically target TDP-43 pathology in ALS recently granted FDA Fast Track Designation for expedited review.
The trial participant was treated at the lead clinical trial site, the Sean M Healey & AMG Center for ALS at Mass General Brigham, a premier treatment centre for neurodegenerative diseases and pioneering research.
Olga Uspenskaya-Cadoz, Chief Medical Officer of VectorY, commented: “This trial marks the first ever clinical evaluation of a therapy designed to holistically target TDP-43 pathology in ALS, and thereby reduce TDP-43 aggregation, correct mis-splicing abnormalities, and restore normal nuclear function, and we are excited to advance this novel potential therapeutic strategy to a community of patients who are actively looking for hope.”
PIONEER-ALS is a multicentre, open label, dose-escalation Phase I/II clinical study that will evaluate two dose levels of VTx-002. To optimise the path to pivotal clinical development, secondary and exploratory endpoints of the trial include assessment of the post-treatment Neurofilament light chain (NfL) and novel TDP-43 pathway-related biomarker trajectories, as well as clinical endpoints, including ALSFRS-R, slow-vital capacity, hand-held dynamometry and survival.
“VTx-002 is engineered to enable sustained, localised delivery of an antibody targeting pathological TDP-43, a hallmark of ALS, with the goal of addressing a central driver of disease progression,” said Global Coordinating Investigator James Berry, Chief of the Division of Motor Neuron Diseases and director of the Neurological Clinical Research Institute (NCRI) at Mass General Brigham. “The initiation of this study reflects an innovative approach aimed at one of the most important pathological features of the disease. I look forward to leading this exploration of VTx-002 and its potential to impact people living with ALS.”
